January 10, 2019
Pairing a novel personalized cancer vaccine with an established immunotherapy drug administered to patients in a new way, Harvard Medical School scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery. This two-pronged approach to […]
